
Wearable hydration monitor could help prevent heatstroke, scientists say
Developed by researchers at the University of Texas, the non-invasive device continuously measures hydration levels in real time and wirelessly transmits the data to a smartphone, according to an SWNS report.
"Dehydration is a silent threat that affects millions of people every day," said Professor Nanshu Lu of the University of Texas at Austin, who led the study.
"Our wearable sensor provides a simple, effective way to monitor hydration levels in real time, empowering individuals to take proactive steps to stay healthy and perform at their best," she added, per SWNS.
The sensor uses a method called bioimpedance, which sends a small, safe electrical current through the body via strategically placed electrodes.
The current's flow depends on how hydrated the tissues are — hydrated tissue allows the current to pass easily, while dehydrated tissue resists the flow, according to SWNS.
"Arm bioimpedance is not only sensitive to hydration changes, but also aligns closely with whole-body hydration measurements," said study co-author Dr. Matija Jankovic, a post-doctoral researcher in Professor Lu's lab.
"Dehydration is a silent threat that affects millions of people every day."
"This means the sensor can be a reliable surrogate for tracking hydration levels, even during everyday activities like walking, working or exercising," Jankovic added.
To validate the device, the research team conducted multiple experiments, including a diuretic-induced dehydration study and a 24-hour real-life trial.
Participants were given medication to promote fluid loss. Their hydration levels were monitored via the wearable and compared to urine samples.
The device showed a strong correlation between changes in arm bioimpedance and total body water loss, SWNS reported. The findings were published in the Proceedings of the National Academy of Sciences.
The new sensor could offer an accessible and wearable alternative to traditional hydration tracking methods, such as urine or blood analysis, which are invasive, time-consuming and impractical, the researchers noted.
Hydration is known to be essential for regulating body temperature, maintaining organ function and supporting many other vital processes.
Even mild dehydration can impair concentration and performance, while severe dehydration may lead to serious health problems like heatstroke, kidney stones and cardiovascular issues, according to experts.
Beyond everyday use, the researchers believe the technology could benefit patients with chronic dehydration, kidney disease or heart conditions. Athletes, too, could use the wearable to stay safe and perform optimally, especially in hot weather.
While the current model tracks relative hydration changes, Professor Lu said the team aims to develop reference data for absolute hydration levels.
They are also exploring more advanced wearable formats, like breathable electronic tattoos or sweat-absorbing patches, to enhance comfort during long-term use.
For more Health articles, visit www.foxnews.com/health
"This is just the beginning," Professor Lu said, per the SWNS report. "Our goal is to make simple hydration monitoring accessible to everyone."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
2 minutes ago
- Forbes
OpenEvidence's Meteoric Rise Is Huge For Doctors
Medical research and science has never been easier to access. OpenEvidence has raised hundreds of millions of dollars. In its most recent funding round, it raised a $210 million Series B from prominent investors such as Google Ventures and Kleiner Perkins, bringing the company's valuation to nearly $3.5 billion. The company's goal is straightforward and incredibly ambitious: to collate the entire corpus of medical knowledge and research developments in a way that is easily accessible to physicians and thereby, improve health outcomes. The service is aiming to provide a similar 'touch and feel' as other generative AI services such as Chat GPT or Google's Gemini—except, its target audience is primarily doctors. Medical science is a rapidly evolving field with a perpetually expanding sea of knowledge, especially as research and development across the fields of disease, therapeutics and human sciences continue to grow. In fact, as Sequoia Capital notes, 'a new PubMed article [which is often the flagship resource for peer-reviewed science studies]The value of this type of technology is increasingly being recognized. The latest models for OpenAI's ChatGPT (GPT 4.1 and o3) have displayed incredible efficacy in taking command of medical knowledge; in May, the company published its work with HealthBench, proposing a rubric for model performance in healthcare and also indicating that GPT's latest models performed at par or even better than standard physician evaluations. Even Google's Gemini family of models has made significant progress in this space; its MedLM suite, for example, is a highly tuned model that can aid the entire healthcare workflow, ranging from answering medical questions to deciphering unstructured health data. Why is all of this important? There are a few different reasons. First and foremost, this technology is aiming to democratize medical knowledge in a way that is easy to access. Furthermore, it comes at a time when the healthcare system, and its respective workforce, is facing unprecedented headwinds. Studies have repeatedly indicated that physician burnout and attrition are incredibly concerning problems for health systems and organizations of all sizes; physicians simply do not have the bandwidth to fulfill all of their patient care duties in addition to the increasingly prevalent administrative, compliance and regulatory burdens placed on them. This also means that there is less time for professional development and continuing education. These technologies can serve as a major advantage to the physician workflow as they provide an opportunity to easily query, fact-check and understand the latest science that is involved with a condition. Carry this even further with tools such as OpenEvidence DeepConsult, which gives physicians access to PhD-level AI agents that can conduct medical research, or Gemini's foundation models that can rapidly decipher medical images, or even AI scribing technology that can rapidly generate patient-physician encounter notes, and soon, hours can be saved from a physician's daily workflow. This translates not only to millions of dollars saved annually in system costs, but also to more time available to spend with patients, improved access to care, and ultimately, increased efficacy and quality of care provided.
Yahoo
29 minutes ago
- Yahoo
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. Multipotency refers to a flexible cellular state in which a cell has the potential to differentiate into multiple specialized cell types, depending on the environmental conditions or stimuli it encounters. While stem cells have garnered the most attention on being multipotent, fibroblasts are also considered multipotent and can be directly differentiated into many cell types including chondrocytes, osteocytes, hepatocytes and cardiomyocytes. This patent application broadly relates to methods for generating multipotent cells directly from fibroblasts found in human donor tissues. 'This method provides us with the ability to obtain larger quantities of stable and easily scalable multipotent cells from donor-derived fibroblasts for use in clinical applications,' said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. 'Multipotent fibroblasts also show enhanced ability to form 3D spheroid structures, further expanding their potential across a range of therapeutic and drug development areas.' Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics, said, 'By enabling the generation of stable, multipotent cells directly from donor tissue, this innovation addresses long-standing challenges in the field and opens new possibilities for scalable, regenerative treatments.' For more information, please visit FibroBiologics' website or email FibroBiologics at info@ Cautionary Statement Regarding Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of multipotent fibroblasts across a range of therapeutic and drug development areas and new possibilities for scalable, regenerative treatments. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit General Inquiries:info@ Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347) in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio
The new AI-powered Smart Food Logging feature supports greater personalized insights into how meals are impacting glucose levels Users can now take a photo of their food in their Stelo or Dexcom G7 app where AI will automatically identify the ingredients and populate the meal description SAN DIEGO, July 28, 2025--(BUSINESS WIRE)--DexCom, Inc., the global leader in glucose biosensing, announced today it has released a new AI-powered photo meal logging feature to Stelo, the first over-the-counter glucose biosensor cleared1 by the FDA in the United States, following the feature's launch on Dexcom G7 earlier this year. Dexcom's Smart Food Logging feature encourages and enables users to log their meals more consistently. Stelo and Dexcom G7 users can now simply take a photo of their food in the app where AI will automatically identify the ingredients and populate the meal description. Dexcom G7 is the only prescription continuous glucose monitor in the U.S. to support photo logging2,3. "Diet plays a crucial role in managing glucose levels, and our new Smart Food Logging feature removes barriers to food tracking, making it easier to consistently log and understand the impact of meals," said Jake Leach, president and chief operating officer at Dexcom. "Smart Food Logging has long been a highly requested feature from users across our product portfolio, so we're excited to bring it to market and hope this enhanced tracking feature makes managing glucose levels even simpler." The addition of Smart Food Logging is yet another demonstration of Dexcom's commitment to continued innovation and AI. This new feature joins other recently announced enhancements across Dexcom's glucose biosensing portfolio, including: Weekly Insights in Stelo: The first GenAI feature in Stelo, which offers users more personalized tips, recommendations, and education related to diet, exercise, and sleep that are contextualized within the Stelo app. Stelo integration with Oura: The first-ever integration of glucose biosensing data in the Oura app. When Stelo is synced with Oura, users have a holistic view of their body's biometrics, now including glucose. This integration empowers users to understand the impact of different health behaviors and work towards optimal metabolic health. Customizable target range in Dexcom G7: A new feature that enables users to adjust their glucose target ranges in Clarity Card within the Dexcom G7 app, beyond default settings – allowing for greater personalization across user groups. Glucose Impact in Dexcom G7 and Stelo: Glucose Impact offers a new focused view for logged events to see a clearer picture and gain a deeper understanding of how meals, activities, and sleep patterns affect your glucose levels. Stelo and Dexcom G7 users can now access the Smart Food Logging feature by updating to the latest version of the app on iOS and Android platforms. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you're made of. For more information, visit Category: IR 1 Dexcom, Stelo User Guide, 2024. 2 Based on Freestyle Libre User Guides. 3 Based on Medtronic User Guides. View source version on Contacts Media Relations Contact Nadia Conardmediarelations@ Investor Relations Contact Sean Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data